AVANTGEN INC
SAN DIEGO, CA · Medtech · Private
Point-of-care diagnostic device for Hepatitis C virus detection
- Grants
- $6.6M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $13M
- 15 awards · Health and Human S
- #56 of 4531 in medtech
- Patents
- 13
- 1 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2008201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Health and Human Services · Renewable Captors For Addiction-relevant Proteins | $198,000 | |
| Federal contract | Department of Health and Human Services · TAS::75 0872::TAS Recombinant Antibodies As Affinity Captures | $149,951 | |
| Federal contract | Department of Health and Human Services · TAS::75 0849::TAS Development Of Alternative Affinity Capture Reagents For Cancer Proteomics Research | $150,000 | |
| Federal contract | Department of Health and Human Services · TAS::75 0893::TAS Renewable Captures For Addiction-relevant Proteins | $764,548 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf Other Functions - Recombinant Antibodies As Affinity Captures | $990,779 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf Other Functions SBIR Phase II, Topic 288, "recombinant Antibodies As Affinity Captures" | $747,441 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf Recombinant Rabbit Monoclonal Antibodies As Affinity Captures For Peptides | $199,987 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel approach for developing antibody reagents to probe changes in the synapse p | $756,189 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a highly specific and sensitive glucagon ELISA kit | $224,670 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a highly specific and sensitive glucagon ELISA kit | $224,670 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf Recombinant Rabbit Monoclonal Antibodies As Affinity Captures For Peptides | $999,996 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel approach for developing antibody reagents to probe changes in the synapse p | $805,808 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf Topic 372 - SBIR Phase I: Development And Validation Of Non- Mouse Reagents To Enable Preclinical Development Of Novel Therapeutics - Moonshot | $299,854 | |
| Federal contract | Department of Health and Human Services · Topic 372: Development And Validation Of Non-mouse Reagents To Enable Preclinical Development Of Novel Therapeutics | $1,995,852 | |
| Federal contract | Department of Health and Human Services · Development Of Rabbit Monoclonal Antibodies For Ferret Biomarkers | $356,021 | |
| Federal contract | Department of Health and Human Services · Development Of Rapid And Point-of-care Diagnostic Kit For Hepatitis C Virus Detection | $300,000 | |
| Federal contract | Department of Health and Human Services · Rapid Acceleration Of Diagnostics (radx) Program: Tech Project #7360 - Highly Sensitive Rapid Test Kit For SARS-COV-2 That Does Not Require A Reader | $3,750,864 | |
| Federal contract | Department of Health and Human Services · Development Of Rabbit Monoclonal Antibodies For Indian Flying Fox (bat) Biomarkers | $592,751 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) | $1,398,552 | |
| Federal contract | Department of Health and Human Services · Development Of Rabbit Monoclonal Antibodies For Ferret Biomarkers. | $1,497,384 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) | $574,272 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 53 | INFRASCAN INC | $14M | — |
| 54 | Polestar Technologies, Inc. | $14M | — |
| 55 | SIMQUEST INTERNATIONAL, LLC | $13M | — |
| 56 | AVANTGEN INC | $13M | — |
| 57 | TETRACORE, INC. | $13M | — |
| 58 | Volcano Corporation | $12M | — |
| 59 | REDUX INC | $12M | $1.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Novel Peptides And Uses Thereofapplication
- Novel Peptides And Uses Thereofgranted
- Agents That Bind To CD16A And Uses Thereofapplication
- Agents That Bind To CD16A And Uses Thereofapplication
- Agents That Bind To CD16A And Uses Thereofapplication
- SARS-COV-2 Binding Agents And Uses Thereofapplication
- SARS-COV-2 Binding Agents And Uses Thereofapplication
- SARS-COV-2 Binding Agents And Uses Thereofapplication
- SARS-COV-2 Binding Agents And Uses Thereofapplication
- SARS-COV-2 Binding Agents And Uses Thereofapplication
- Agents That Bind To CD16A And Uses Thereofapplication
- Novel Peptides And Uses Thereofapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.